Introduction to Peptide Compounding & FDA Regulation
A beginner's guide to how FDA regulates peptide compounding under Section 503A, what PCAC does, and how compounding eligibility differs from drug approval.
Peptide research compounds like BPC-157, TB-500, and KPV are frequently discussed alongside a specific piece of U.S. regulatory machinery: the FDA's Section 503A Bulks List and its Pharmacy Compounding Advisory Committee (PCAC). For researchers unfamiliar with pharmacy compounding law, the terminology in FDA briefing documents and news coverage can be confusing — a "recommendation" is not an "approval," a "bulk drug substance" is not a "finished drug," and a compounding pathway is not a marketing authorization.
This guide explains the regulatory framework itself, independent of any single compound's review outcome, so that later readers of compound-specific articles or FDA briefing documents have the necessary background to interpret them accurately.
What Compounding Pharmacies Do
Pharmacy compounding is the practice of preparing a customized medication for an individual patient when a commercially available, FDA-approved drug does not meet that patient's specific needs — for example, a different strength, an alternate dosage form, or removal of an ingredient the patient is allergic to. Compounded drugs are not FDA-approved; they are prepared under a different section of the Federal Food, Drug, and Cosmetic Act (FD&C Act) than commercially manufactured pharmaceuticals.
Section 503A of the FD&C Act describes the conditions under which a licensed pharmacist or physician may compound a drug for an identified patient and receive exemptions from several requirements that would otherwise apply — including the requirement that a drug be the subject of an approved new drug application. []
What Section 503A Requires of a Bulk Drug Substance
Not every chemical can be used in 503A compounding. FDA explains that a bulk drug substance generally must satisfy one of a short list of conditions: it complies with an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, it is a component of an FDA-approved drug when no monograph exists, or it appears on FDA's 503A Bulks List after agency review. Additional conditions apply as well, including requirements about the substance's source and accompanying certificate of analysis. []
Peptides like BPC-157 or TB-500 do not have USP/NF monographs and are not components of an FDA-approved drug, which is why their only potential path into 503A compounding runs through the Bulks List review process — the process PCAC advises on.
What PCAC Is and What It Does
The Pharmacy Compounding Advisory Committee is a standing FDA advisory committee made up of outside experts who review nominated bulk drug substances and give the agency scientific and technical recommendations. FDA evaluates each nominated substance against four criteria: physical and chemical characterization, safety issues, available evidence of effectiveness (or lack of it), and historical use in compounded drug products. []
PCAC does not vote on whether a drug should be approved, and it has no independent authority to add a substance to the Bulks List. Its recommendations are advisory. FDA reviews the committee's discussion, the public record, and its own evidentiary analysis before deciding what, if anything, to do next. []
Why Peptides Present a Recurring Characterization Problem
Across PCAC's peptide reviews, several issues have appeared repeatedly regardless of which specific compound was under discussion:
Free base vs. acetate forms. Many nominated peptides exist in more than one salt or chemical form, and FDA treats each form as a distinct bulk drug substance requiring separate characterization, since form can affect stability, purity profile, and product performance.
Naming inconsistency. The same peptide is sometimes referred to by multiple names across nomination materials, complicating identity verification.
Limited human data. For several reviewed peptides, FDA reported that it did not identify any published human administration studies at all — meaning the evidentiary record was built almost entirely from cell culture and animal research.
Impurity and aggregation concerns. Peptide synthesis and storage can introduce process-related impurities or cause aggregation, both of which raise potential immunogenicity questions that are harder to characterize than they are for small-molecule drugs.
A Worked Example: The July 2026 Peptide Reviews
The clearest illustration of this framework in practice is FDA's July 23–24, 2026 PCAC meeting, which reviewed seven peptide-related bulk substance groups: BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax, and Epitalon. PCAC recommended six of the seven for inclusion; only Emideltide/DSIP did not receive a favorable recommendation. FDA staff's own preliminary position, notably, weighed against listing any of the seven. []
That disagreement between FDA staff and the committee is itself instructive: a favorable PCAC vote does not mean the underlying evidence gaps described in FDA's briefing documents disappeared. It means a majority of committee members judged the overall balance of considerations — including clinician access and demand — differently than FDA staff did. For the complete vote table, evidentiary themes, and next regulatory steps, see the FDA PCAC peptide review hub.
Three Concepts That Are Not the Same Thing
Reporting and online discussion of these reviews frequently blur three distinct regulatory concepts:
| Concept | What it means | What it does not mean |
|---|---|---|
| PCAC recommendation | Advisory committee's nonbinding opinion on Bulks List eligibility | Not a legal or regulatory action by itself |
| 503A Bulks List inclusion | FDA has determined a bulk substance may be used in qualifying compounding | Not FDA approval of a finished drug, dose, or indication |
| FDA drug approval | A sponsor's marketing application was reviewed and authorized for a specific product and use | An entirely separate, more rigorous pathway that none of these peptides has completed |
Confusing these three is the single most common misunderstanding in peptide research discussions of FDA activity. A compound with a favorable PCAC recommendation is not "FDA approved," is not necessarily safe, and has not had its effectiveness for any specific condition established by the review.
How to Read Future PCAC Reviews
When a new peptide substance comes up for PCAC review, the same questions apply regardless of which compound it is:
- Which specific chemical form (free base, acetate, or another salt) was actually reviewed?
- What use or condition did FDA evaluate — and does it match the claims circulating about the compound?
- Did FDA identify any human clinical data, or is the evidentiary record limited to preclinical models?
- Did PCAC's recommendation agree or disagree with FDA staff's preliminary position?
- Has FDA taken any final action, or does the recommendation remain pending?
Our guides to reading peptide research and evaluating peptide research claims provide a complementary framework for the underlying science; this guide is meant to provide the regulatory vocabulary needed to interpret compounding-related news accurately.
Frequently Asked Questions
Does 503A Bulks List inclusion mean a peptide is FDA approved?
No. Bulks List inclusion addresses whether a bulk drug substance may be used in qualifying pharmacy compounding when other statutory conditions are met. It is a separate, less rigorous pathway than FDA drug approval, which evaluates a specific finished product, dose, and indication.
Can PCAC add a substance to the Bulks List on its own?
No. PCAC only advises FDA. The agency retains full decision-making authority and may accept, reject, or modify the committee's recommendation.
Why does FDA treat free base and acetate forms of the same peptide separately?
Because salt form can affect a substance's chemical characterization, stability, impurity profile, and product performance, FDA evaluates each form as a distinct bulk drug substance rather than assuming findings for one automatically apply to the other.
What happens if FDA disagrees with a PCAC recommendation?
FDA is not bound by PCAC's advice. The agency can proceed differently from the committee's recommendation, as it has done in prior compounding reviews across other drug categories.
References
- 1.U.S. Food and Drug Administration. “Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.” 2026. [Link]
- 2.U.S. Food and Drug Administration. “July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.” 2026. [Link]
- 3.U.S. Food and Drug Administration. “FDA Briefing Document: Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026.” 2026. [Link]
- 4.Eglovitch JS. “FDA advisory committee backs two more peptides, rejects one for compounding list.” Regulatory Focus, Regulatory Affairs Professionals Society. 2026. [Link]